Takeda hikes outlook on cancer drug sales, Q3 profit jumps 60%
Add BT as a preferred sourceTokyo
TAKEDA Pharmaceutical Co Ltd said that its annual profit will outstrip a prior estimate and reach a six-year high, boosted by stronger sales of the cancer drug Velcade, after earlier reporting better-than-expected quarterly earnings.
Velcade is used to treat multiple myeloma, a type of blood cancer. A US court last year upheld Takeda's patent, giving the drug maker rights to exclusively sell the drug until 2022.
TRENDING NOW
Ex-Sakae director Ong Siew Kwee handed 10.5-year jail term for misappropriating S$15.8 million, lying in court
DBS sees choppy Q3 for STI as investors pivot from Singapore banks to listcos that’re unlocking value
Yeoh Pei Xien: YTL’s third-gen scion with a pastor’s heart
High Court rejects bid to bring ST Engineering unit into trademark infringement suit over RSAF aircraft parts
